1. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022) Authors: Foley, John F; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan; van der Walt, Anneke; Dwyer, Christopher; Bu... Journal: Lancet neurology Issue: Volume 21:Issue 7(2022) Page Start: 608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. (March 2022) Authors: Rascol, Olivier; Tönges, Lars; deVries, Tina; Jaros, Mark; Quartel, Adrian; Jacobs, David; Azulay, Jean-Philippe; Balaguer, Ernest; Bhatia, Perminder; Bodis-Wollner, Ivan; Brownstone, Paul; Boulloche, Nicolas; Calegan, Gerald J.; Castelnovo, Giovanni; Chou, Kelvin L.; Corvol, Jean-Christophe; Dan... Journal: Parkinsonism & related disorders Issue: Volume 96(2022) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2020) Authors: Cree, Bruce A C; Cutter, Gary; Wolinsky, Jerry S; Freedman, Mark S; Comi, Giancarlo; Giovannoni, Gavin; Hartung, Hans-Peter; Arnold, Douglas; Kuhle, Jens; Block, Valerie; Munschauer, Frederick E; Sedel, Frédéric; Lublin, Fred D; Reingold, Stephen; Duquette, Pierre; Derfuss, Tobias; Fazekas, Franz... Journal: Lancet neurology Issue: Volume 19:Issue 12(2020) Page Start: 988 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗